Unfortunately, placebo response rates have been rising over the past few decades in fields that rely on patient-reported outcome measures, including analgesia trials. This has led to some serious consequences that keep treatments away from the patients who need them:
- A higher chance of a negative trial outcome despite a product’s actual effectiveness
- High financial costs that lead many pharmaceutical companies to abandon promising novel products
- Drugs with potentially broad applications being approved for only narrow indications
In The Placebo Problem, analgesia trial experts Michael Kuss, BS, VP, Analgesia, and Scott Millard, Executive Director, Strategic Development, Analgesia, explain the history of the placebo response, its impact on modern drug development, and what strategies for minimizing it are currently in development.